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Objectives Fatty acid oxidation (FAO) and glycolysis have been implicated in immune 
regulation and activation of macrophages. However, investigation of human monocytes 
intracellular metabolism in the context of the hypoxic and inflammatory rheumatoid arthritis 
(RA) synovium is lacking. We hypothesised that exposure of monocytes to the hypoxic and 
inflammatory RA environment would have a profound impact on their metabolic state, and 
potential to contribute to disease pathology. 
Methods Human monocytes were isolated from buffy coats and exposed to hypoxia. 
Metabolic profiling of monocytes was carried out by LC-MS metabolomics. Inflammatory 
mediator release after LPS or RA-synovial fluid (RA-SF) stimulation was analysed by 
ELISA. FAO was inhibited by etomoxir or enhanced with exogenous carnitine 
supplementation. Transcriptomics of RA blood monocytes and RA-SF macrophages was 
carried out by microarray. 
Results Hypoxia exacerbated monocyte-derived CCL20 and IL-1β release in response to 
LPS, and increased glycolytic intermediates at the expense of carnitines. Modulation of 
carnitine identified a novel role for FAO in the production of CCL20 in response to LPS. 
Transcriptional analysis of RA blood monocytes and RA-SF macrophages revealed that fatty 
acid metabolism was altered and CCL20 increased when monocytes enter the synovial 
environment. In vitro analysis of monocytes showed that RA-SF increases carnitine 
abundance and CCL20 production in hypoxia, which was exacerbated by exogenous 
carnitine. 
Conclusion This work has revealed a novel inflammatory mechanism in RA that links FAO 
to CCL20 production in human monocytes, which could subsequently contribute to RA 









1. Hypoxia modifies monocyte metabolism and exacerbates the release of pro-
inflammatory mediators. 
2. The RA synovial milieu severely alters fatty acid metabolism, which supports the 




















Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by immune-
mediated pathology and articular destruction. Enhanced metabolic turnover and a disrupted 
vasculature creates hypoxic regions (<1% O2) within the affected synovium in comparison to 
the normal synovium which can range from 5-8% O2  (1,2). Such low pO2 levels in the RA 
synovium likely contribute to infiltration of leukocyte subsets that in turn drive disease 
pathogenesis (3). Monocytes and macrophages are considered central to pathogenesis by 
virtue of their capacity to release inflammatory cytokines, chemokines and reactive oxygen 
and nitrogen intermediates. They can be activated by various molecules such as immune 
complexes, TLR agonists, complement factors, T cell cognate interactions and thereby drive 
chronicity. Infiltrating monocytes, therefore, must undergo substantial metabolic adjustment 
in this context that likely confers functional impact on their behaviours and contribution to 
pathology.  
Although largely studied in experimental settings, metabolic pathways, such as glycolysis 
and fatty acid β-oxidation (FAO), are increasingly implicated in the governance of immune-
mediated cascades in macrophages. Glycolysis is one of the best characterised metabolic 
pathways in the immune-metabolic field. In particular, glycolysis is thought to drive the 
inflammatory phenotype of M(LPS ± IFNg) macrophages and the production of IL-1β in a 
process mediated by succinate accumulation and HIF-1α  (4,5).  FAO is a mitochondrial 
process whereby fatty acids are converted to products such as acetyl-CoA to generate energy. 
In order for medium and long-chain fatty acids to enter the mitochondria for oxidation, they 
are first conjugated to free carnitine by the enzyme, carnitine palmitoyltransferase I (CPT1). 
This complex is then shuttled through the mitochondrial membrane where fatty acid acyl-
 
CoA groups are released from carnitine into the mitochondrial matrix by carnitine 
palmitoyltransferase II (CPT2) for subsequent oxidation (6). FAO was considered essential 
for the induction of the M(IL-4) murine macrophage metabolic programme (7,8), although 
this notion has been challenged in the ‘equivalent’ M(IL-4) macrophage phenotype in 
humans, where FAO appears to be dispensable (9). There is evidence, however, to suggest 
that FAO can dampen immune responses in macrophage cell lines in response to palmitate 
(10). How FAO influences specific functions in human myeloid cells remains poorly 
understood. 
Furthermore, there are only a limited number of studies on immune-metabolism in the 
context of RA. It has previously been shown that monocytes and macrophages from RA 
patients express high levels of α-enolase (a glycolytic enzyme) on the cell surface, which can 
be bound mainly in citrullinated form, by autoantibodies to induce the production of 
inflammatory cytokines including TNFα and IFNγ (11). More recent studies interrogating 
macrophages derived from RA patients, defined increases in both mitochondrial and 
glycolytic metabolism, associated with a hypermetabolic profile (12). Moreover, RA synovial 
fluid (RA-SF) derived succinate has been shown to signal through GPR91 to promote IL-1β 
release from murine macrophages (13). 
We set out, therefore, to define the impact of key components of the synovial 
microenvironment on monocyte metabolism using hypoxia and TLR agonists as surrogates, 
and RA synovial fluid as a definitive stimulus. We report that the production of CCL20 is 
regulated by the FAO set-point in monocytes, which is heavily influenced by the 
microenvironment to which they are exposed. Taken together, we have uncovered a key 
novel pathway that could contribute to disease pathogenesis through the recruitment of 






Detailed information of the following methods are provided in the online supplementary data. 
 
Human samples, patients and controls 
Buffy coats from the Scottish National Blood Transfusion Service (SNBTS) from healthy 
volunteers were used to isolate primary human cells. Synovial fluid was obtained from 
rheumatoid arthritis (RA) patients, which were identified from Rheumatology clinics at the 
Glasgow Royal Infirmary and fulfilled the 2010 ACR/EULAR criteria for RA. All samples 
were obtained after written consent, with the appropriate ethical approvals in place. Patient 
characteristics for microarray analysis are illustrated in (18). Synovial fluid was obtained 
from RA patients with active disease that required aspiration of a joint with effusion. 
Primary human monocyte isolation and culture 
Peripheral blood mononuclear cells (PBMCs) were separated from human blood buffy coats 
by density gradient centrifugation and monocytes purified using the EasySep monocyte 
enrichment kit, without CD16 depletion (StemCell Technologies). Human monocytes were 
stimulated with either 10 ng/ml LPS-EK ultrapure (Invivogen) or 10% RA synovial fluid. For 
carnitine manipulation, monocytes were treated with 10 mM L-carnitine (Sigma-Aldrich) 
simultaneously with LPS or RA synovial fluid stimulation. Monocytes were pre-treated for 1 
hour with etomoxir (ETO; Sigma-Aldrich) at 50 µM. 
Induction of hypoxia 
For the induction of hypoxia (1% O2), an airtight hypoxic chamber was utilised (Billups-
Rothenburg). For culture in normoxia (20% O2), cells were cultured in ambient oxygen in a 
standard 37°C tissue culture incubator. 
Extraction of monocyte intracellular metabolites 
 
Intracellular metabolites were harvested from monocytes by chloroform:methanol:water 
(1:3:1 ratio) extraction at ≤4°C. Samples were stored in screw-capped vials at -80°C until 
analysis. 
Untargeted Liquid Chromatography Mass Spectrometry (LC-MS) 
Hydrophilic interaction liquid chromatography (HILIC) was carried out on a Dionex 
UltiMate 3000 RSLC system (Thermo Fisher) using a ZIC-pHILIC column (Merck Sequant). 
For the MS analysis, a Thermo Orbitrap Q Exactive (Thermo Fisher) was operated in both 
positive and negative mode.  
Processing of MS data 
Processing of the raw data and analysis was performed using a processing pipeline through 
IDEOM Excel based software (17). According to the metabolomics standards initiative 
(MSI), metabolite identifications (MSI level 1) are given when more than one feature 
matches an authentic standard (i.e. mass and retention time) and annotations are made when 
matching to a metabolite is made by mass only (MSI level 2), and should be considered 
putative. Normalised data was used in generating the principal component analysis (PCA) 
and heatmaps. PCA was performed on the processed metabolite data using the R (v.3.4.4) 
function prcomp. Heatmaps of significant metabolites were hierarchically clustered using the 
R package hclust, with the distance method Spearman and cluster method Average. The data 
was then scaled into per metabolite z-scores (i.e. distance from the mean in units of standard 
deviations) using the R function scale. 
Microarray Analysis 
RNA purification and microarray analysis of samples from matched RA blood and SF 
derived CD14+ cells was conducted as previously described (18). In brief, the raw data (.CEL 
files) were processed and normalised using R (version 3.4.4). The R WGCNA package was 
used to collapse multiple genes down to a single value using the “MaxMean” method. 
 
Differential expression was determined using the R package LIMMA (19) with a significance 
threshold of adjusted p < 0.05 and a fold change > 2. Enriched gene-sets were determined 
using a hypergeometric test with Benjamini-Hochberg correction at p < 0.05. The collapsed 
probe-set was used as the background, and a combination of the following MsigDB (20) 
collections were used in the analysis: canonical pathways, BIOCARTA, KEGG, 
REACTOME and GO. 
ELISA & Meso-Scale Discovery (MSD) 
Supernatant analysis of IL-1β (Life Technologies) and CCL20 (R&D Systems) was carried 
out by ELISA according to the manufacturer’s instructions.  
TNFα, IL-1β and IL-6 supernatant were also analysed by using the V-PLEX Pro-
inflammatory panel 1 from MSD according to the manufacturer’s protocol.  
Statistical Analysis 
Statistical analysis was performed in GraphPad Prism 6 software. All data are shown as the 
mean ± standard deviation (SD) unless otherwise stated. The statistical test used for each 
experiment is indicated in the figure legend. A p value of less than 0.05 was considered 
significant.  
Data Availability 
The microarray array data is MIAME compliant and has been deposited to the ArrayExpress 
database (http://www.ebi.ac.uk/arrayexpress) with the accession number: E-MEXP-3890. 







Hypoxia enhances the release of pro-inflammatory mediators from LPS stimulated 
human monocytes 
We initially set out to confirm that hypoxia, as observed in the synovial microenvironment, 
would potentiate the ability of human monocytes to secrete pro-inflammatory mediators (21). 
Human monocytes from healthy individuals were exposed to hypoxic conditions and 
stabilisation of HIF-1α was verified (Figure 1A). We analysed the secretion of IL-1β, IL-6, 
TNFα and CCL20 in both resting and LPS-activated monocytes exposed to hypoxia for 16 
hours. CCL20 was included, as it had previously been reported to be a hypoxia-inducible 
chemokine in human monocytes (22). Unstimulated monocytes did not spontaneously secrete 
any of the evaluated cytokines or chemokines when cultured in normoxia (Figure 1B). 
Moreover, hypoxia alone did not induce release of IL-1β, IL-6, TNFα or CCL20 (Figure 1B). 
LPS induced secretion of IL-1β, IL-6, TNFα and CCL20 in monocytes in normoxia, and this 
was significantly increased by hypoxia (Figure 1B). Notably, there was a four-fold increase 
in the release of CCL20 in hypoxic conditions compared to normoxia (p = 0.001). With 
regards to TNF secretion, this was a donor-specific phenomenon (Figure 1B). These data 
suggest that upon adaptation to a hypoxic inflammatory environment, monocytes are primed 
to enhance their ability to secrete pro-inflammatory mediators. 
Short-term hypoxia reduces carnitine abundance in human monocytes 
We postulated that hypoxia-specific metabolic reprogramming was priming monocytes to 
augment their ability to secrete inflammatory cytokine/chemokines in response to LPS. Using 
the same hypoxic culture system, we first examined how monocytes metabolically adapted to 
low pO2 by conducting LC-MS based metabolomics. PCA analysis revealed that monocytes 
exposed to hypoxia exhibited a distinct metabolic profile to those cultured in normoxia 
 
(Figure 2A). Monocytes exposed to hypoxia had 23 significantly altered metabolites.  
Thirteen of these metabolites were of higher abundance in hypoxic conditions, while 10 
metabolites were of lower abundance (Figure 2B & Supplementary Table 1). This 
corresponded to increased glycolytic and purine intermediates and decreased mitochondrial-
associated metabolites (Supplementary Table 1). Further interrogation of the mitochondrial-
associated metabolites revealed that one of the most prominent reductions was in the 
acylcarnitine, O-propanoylcarnitine (Figure 2C). Interestingly, we also observed donor 
specific decreases in free carnitine (L-carnitine) and another acylcarnitine, 2-
methylbutyroylcarnitine (Figure 2C). This suggested that carnitine shuttling (Figure 2D) is 
altered during the adaptation process to hypoxia, and that this change could have a 
subsequent negative impact on downstream FAO.  In contrast to carnitine metabolites, a 
reverse effect was observed in glycolytic-associated metabolites. Notably, of the 8 glycolytic 
metabolites that were putatively identified, 4 were significantly up-regulated after 4 hours of 
hypoxia. We observed an increase in the glycolytic intermediates 3-P-glycerate, fructose-1-6-
bisphosphate glyceraldehyde-3-P and D-glucose (Figure 2E). This was associated with a 
significant increase in the transcript level of the glycolytic enzymes GLUT-1, HK2, PGK1 
and LDHA (Supplementary Figure S1). Evaluation of intermediates involved in purine 
metabolism revealed that select metabolites (IMP and hypoxanthine) were also increased in 
hypoxic conditions (Supplementary Figure S2). Together, these data suggest that glycolytic 
metabolism is increased at the expense of carnitine-dependent FAO for ATP production 
during monocyte adaptation to hypoxia.  
Carnitine modulation implicates a role for FAO in the production of pro-inflammatory 
mediators 
We next tested the notion that the balance between glycolysis and carnitine shuttling (and 
subsequent FAO) provides a functional link to the enhanced secretion of inflammatory 
 
mediators up on adjustment to hypoxic conditions. We pharmacologically blocked carnitine-
dependent FAO. Pre-treatment with etomoxir (ETO, a carnitine palmitoyltransferase I 
[CPT1] inhibitor) significantly increased the level of IL-1β secretion in LPS stimulated cells, 
in both normoxia and hypoxia (Figure 3A). This suggests that ETO shifts cellular metabolism 
towards increased glycolysis, which in turn exacerbates IL-1β production (4). In contrast, 
although ETO significantly increased the production of CCL20 from monocytes in response 
to LPS (p = 0.03) it had no effect on the production of CCL20 in hypoxic conditions (Figure 
3A). We therefore concluded that in normoxic conditions, enhanced glycolysis (via ETO) 
exacerbates CCL20 production. In hypoxia, however, the balance between glycolysis and 
FAO metabolism is such that ETO cannot shift it further and hence there is no increase in 
glycolysis-driven CCL20 production.  
To further investigate the role of these metabolic pathways on cytokine/chemokine release, 
human monocytes (from a distinct donor cohort to the ETO experiments) were cultured in the 
presence of exogenous carnitine (10 mM) to enhance FAO. This concentration was utilised as 
it did not impair monocyte viability (Supplementary Figure S3). Exogenous carnitine had no 
significant impact on the production of IL-1β (Figure 3B). Surprisingly, exogenous carnitine 
significantly enhanced the production of CCL20 from LPS-stimulated monocytes in both 
normoxic and hypoxic (p = 0.0156) conditions (Figure 3B). Together these data suggest that 
both glycolysis and FAO can contribute to the production of CCL20 in human monocytes. 
The precise weighting of these pathways in driving CCL20 production in chronic disease 
may be dependent on the metabolic phenotype induced by specific stimuli and environmental 
factors in the disease state. 
Monocyte adaptation to the RA synovial compartment induces transcriptional 
alterations in CCL20 & fatty acid metabolic pathways. 
 
To investigate if CCL20 and fatty acid metabolism were altered when human monocytes 
adapted to the hypoxic and inflammatory RA synovial environment in vivo, we re-analysed 
microarray data that compared circulating blood monocytes with matched synovial fluid 
macrophages from RA patients (18). Using a 2-fold cut-off and an adjusted p value of 0.05, 
we identified 2217 differentially expressed genes (Figure 4A). Consistent with our in vitro 
data (Figure 1B), CCL20 was significantly increased in RA-SF macrophages (Figure 4B). To 
identify additional pathways that were significantly altered between RA-SF macrophages and 
blood monocytes, we conducted hypergeometric pathway analysis. Interestingly, this analysis 
identified 5 pathways associated with fatty acid metabolism (i.e., FAO and transport) that 
were significantly altered (Figure 4C and Supplementary Figure S4). 
RA-SF increases the abundance of carnitine metabolites in monocytes, which can 
support CCL20 release. 
To interrogate the relevance of these transcriptional changes, we investigated whether 
carnitine-mediated FAO was modified by a surrogate for synovial conditions in vitro. To 
replicate the synovial microenvironment, we cultured monocytes under hypoxic conditions 
and stimulated the cells with media containing RA-SF. The monocyte metabolic profile was 
analysed by LC-MS and LPS was utilised as a comparator stimulus. PCA analysis 
demonstrated that monocytes exposed to hypoxia and RA-SF have subtle differences in 
metabolome compared to those cultured in hypoxia with or without LPS (Figure 5A). 
Subsequent analysis revealed that stimulation of monocytes with RA-SF in hypoxic 
conditions significantly increased (p < 0.05) 33 metabolites in comparison to both hypoxia-
exposed or LPS stimulated hypoxia-exposed monocytes (Figure 5B & Supplementary Table 
2). In particular, analysis at a single metabolite level revealed that L-carnitine and the acyl-
carnitines; 3-dehydroxycarnitine and O-acetylcarnitine, were significantly increased in 
human monocytes by RA-SF in hypoxia. (Figure 5B and 5C). In addition, metabolic 
 
intermediates of purine breakdown (xanthine and urate; Figure 5B and Supplementary Figure 
S6) and creatinine biosynthesis (Supplementary Figure S5) were altered by RA-SF. 
Furthermore, we observed increases in intracellular ATP upon RA-SF treatment 
(Supplementary Figure S7). 
Taking the microarray and in vitro metabolomic analyses together, we hypothesised that 
carnitine shuttling (and potentially FAO) affects cytokine and chemokine secretion (in 
particular, CCL20) in the context of disease-specific (RA-SF) stimulation of human 
monocytes. Therefore, this pathway was inhibited or increased via ETO or exogenous 
carnitine treatment respectively. In contrast to LPS stimulation, RA-SF did not induce 
detectable levels of IL-1β (data not shown). However, RA-SF stimulation was able to induce 
CCL20 secretion, the magnitude of which was donor specific (Figures 6A & 6B). Pre-
treatment with ETO had no observable effect on CCL20 release (Figure 6A). In contrast, the 
addition of exogenous carnitine significantly enhanced the release of CCL20 in hypoxic 
conditions (Figure 6B). Interestingly, in a proportion of donors where no detectable levels of 
CCL20 were observed in hypoxia, treatment with RA-SF resulted in detectable levels of 
CCL20. These results indicate that carnitine shuttling and subsequent FAO potentially has an 





The RA synovial compartment is a complex milieu that contains both stimulating factors and 
hypoxic regions. However, these environmental exposures are not routinely taken into 
consideration in immune-metabolic studies. We have demonstrated that the RA synovial 
environment has profound and distinct effects on the metabolic profile of human monocytes, 
particularly in fatty acid metabolism. This leads to resetting of the balance between FAO and 
 
glycolysis that can determine the levels of CCL20 and IL-1β production. Furthermore, by 
manipulating carnitine levels in vitro, our studies reveal that FAO has an important role in the 
production of CCL20 in both LPS and RA-SF stimulated cells suggesting increased carnitine 
abundance, potentially as part of a hypermetabolic state (12), can drive a CCL20-mediated 
inflammatory cascade to promote disease pathogenesis. 
Our studies confirmed that hypoxia increases glycolytic metabolism at the expense of 
mitochondrial pathways, such as carnitine-dependent FAO, in human monocytes (23,24). 
Increased glycolytic flux is commonly associated with inflammatory macrophages suggesting 
that hypoxia induces a metabolic switch to promote an inflammatory phenotype (4,25). 
Indeed, in response to LPS challenge, hypoxia substantially increased the production of the 
pro-inflammatory cytokines IL-6 and IL-1β, from monocytes. In addition, hypoxia also 
exacerbated CCL20 production, which is consistent with the notion that CCL20 is a hypoxia-
associated factor (21). These data align with a recent study in human macrophages, where 
hypoxia increased the release of IL-6 and IL-1β in response to palmitate (22). Together, this 
suggests that hypoxia acts as an extracellular danger signal that primes a robust inflammatory 
response through transcriptional and metabolic rewiring. 
FAO has been proposed to govern the polarisation of M(IL-4) murine macrophage (7). In 
contrast, recent studies have concluded that FAO has a dispensable role in M(IL-4) 
polarisation in human macrophages (9,26). Leaving us to question what roles FAO may have 
on immune-mediated mechanisms in human myeloid cells. In order to determine if carnitine 
and subsequent FAO plays a role in the exacerbated release of pro-inflammatory mediators, 
carnitine shuttling was targeted for inhibition via ETO or enhanced by supplementation with 
exogenous carnitines. We found that enhancing cellular carnitine through exogenous 
supplements significantly elevated CCL20 release. In addition, exogenous carnitine had 
donor specific effects on IL-1β. Therefore, the precise role of FAO on IL-1β production 
 
warrants further investigation in a larger study. This is however in contrast to previously 
published work, which suggested that carnitine supplementation was immunosuppressive and 
attenuated the release of IL-1β, IL-6 and TNFα from murine macrophages (27). In this 
instance, suppression was observed with 100 mM of L-carnitine treatment. In our 
experimental conditions however, concentrations greater than 10 mM negatively affected 
primary human monocyte viability (Supplementary Figure S3). These data suggest that 
primary human monocytes and murine macrophages have differing sensitivity to, and 
functional consequences upon, exposure to exogenous carnitine. In comparison, carnitine 
shuttling inhibition via ETO substantially increased IL-1β in both oxygen tensions. Treatment 
of prostate cancer cells with ETO has previously been shown to decrease lipid oxidation and 
augment the uptake of glucose, expression of hexokinase-2  and the release of lactate from 
these cells (28). Therefore, the increase in IL-1β under these circumstances could be 
attributed to increased glycolytic flux. Indeed, in M(LPS + IFNγ) macrophages, glycolysis is 
thought to drive increased IL-1β production (4), implying that monocytes and macrophages 
both require glycolytic metabolism to promote IL-1β production. 
Our transcriptomic interrogation demonstrated that fatty acid metabolic pathways are 
severely altered when monocytes infiltrate from the blood and adapt to the RA synovium. In 
support of this concept, in vitro metabolomic analyses revealed increased abundance of 
carnitine and its acyl derivatives, and potentially FAO in RA-SF treated monocytes. Recently 
studies revealed that CD14+ monocytes and in vitro generated macrophages from RA patients 
with active disease also increased mitochondrial metabolism by increasing oxygen 
consumption (12). Interestingly, macrophages from RA patients also exhibit increased 
glycolysis and ATP that suggest RA-associated macrophage are hypermetabolic (12). 
However, in our study RA-SF did not induce any significant alterations in the 3 glycolytic 
intermediates (D-glucose; D-glyceraldehyde-3-P and pyruvate), which were putatively 
 
identified in our untargeted MS dataset. Nonetheless, in support of the study, we did observe 
increases in ATP production in monocytes stimulated in RA-SF (Supplementary Figure S7).  
In addition to the altered fatty acid pathways, our microarray analysis illustrated that CCL20 
was significantly increased upon monocyte adjustment to the RA synovial compartment. 
Therefore, we postulated that the levels of carnitine-mediated FAO could influence the 
release of CCL20 under RA synovial conditions in vitro. In a finding shared with LPS 
stimulated cells, exogenous carnitine exacerbated CCL20 production from human monocytes 
in response to RA-SF in hypoxic conditions. This suggests that intracellular carnitine and 
subsequent FAO promotes CCL20 release in response to cascades induced by a number of 
stimuli that may be present in the RA milieu. The precise signalling events induced by RA-
SF remain elusive and may be heterogeneous amongst patients. Interestingly, in LPS treated 
cells, inhibition of FAO with ETO increased CCL20 only in normoxia. This suggests that in 
hypoxia there was saturated CCL20 release under these conditions. Taken together, our 
carnitine modulation experiments indicate that both FAO and glycolysis could act in 
conjunction to promote CCL20 production. Specifically, these data point to a novel 
inflammatory link between FAO and the production of CCL20. We speculate that increased 
abundance of acylcarnitines and thus, acyl-donors, through carnitine shuttling may increase 
protein acylation to regulate CCL20 production. In support of this, exacerbation of FAO can 
increase the mitochondrial pool of acetyl-CoA, which act as donors for histone 
acetyltransferases (HATs) for the addition of acetyl groups to lysine residues on target 
proteins (29). Indeed, the transcriptional coactivators, CREB-binding protein and p300, 
which have known HAT-activity, have been reported to bind the CCL20 promoter and 
increase gene expression in activated astrocytes and pancreatic β-cells (30,31). Direct 
acylation through acylcarnitine donors could also occur, although little is known about such 
reactions involving acylcarnitines.  
 
Further work is, however, required to identify the exact mechanism for FAO-mediated 
CCL20 release in monocytes. This is important, as CCL20 is being increasingly implicated in 
inflammatory cascades in RA. For example, it has been reported to be secreted by IL-1β 
stimulated fibroblast-like synoviocytes, and can in turn promote chemotaxis of pathogenic 
CCR6+ Th17 cells (32). Moreover, recent studies have shown that CCL20 can induce the 
migration of B cells purified from RA peripheral blood (33). Combined this supports a role 
for infiltrating monocyte-derived CCL20 in promoting pathogenic CCR6+ Th17 and B cell 
accumulation in the RA synovial compartment. A role for CCL20 in osteoblast-mediated 
osteoclast differentiation and subsequent resorption activity in the synovial compartment has 
also been identified (15). This suggests that in addition to promoting adaptive immune cell 
infiltration, CCL20 can enhance bone erosion in the RA joint.  
Overall, this report has elucidated a novel mechanism that links fatty acid metabolism to the 
release of CCL20 from human monocytes in the RA milieu. We propose that upon infiltration 
into the RA synovial environment, monocytes alter their fatty acid metabolic machinery that 
in turn can support CCL20-mediated inflammation in RA (Supplementary Figure S8). Our 
data provide additional supportive evidence that intracellular metabolism can govern 
immunological pathways in chronic inflammatory diseases.   
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Figure 1. Hypoxia exacerbates the release of pro-inflammatory mediators from LPS 
stimulated monocytes. [A] Monocytes cultured for 4h in normoxia (20% O2) or hypoxia (1% 
O2) and immunoblotted for HIF-1α and GAPDH (loading control). Positive control (PC) HeLa 
cell lysate cultured in normoxia (N) or hypoxia (H) was also probed. N = 3 [B] Monocytes 
cultured in normoxia or hypoxia ± LPS (10 ng/ml) for 16h. Cell-free supernatant was harvested 
and assessed by MSD (IL-6, IL-1β & TNFα) and ELISA (CCL20). Statistically analysed by 
paired t Test (IL-6 & IL-1β) or Wilcoxon rank test (CCL20 & TNFα) after D’Agostino & 













Figure 2. Hypoxia alters the metabolome of human monocytes.  Monocytes cultured for 4h 
in normoxia (20% O2) or hypoxia (1% O2) and intracellular metabolites analysed by LC-MS. 
[A] PCA analysis of metabolic profiles obtained from normoxia and hypoxia. [B] Heatmap of 
significantly different metabolites (p ≤ 0.05) between normoxia and hypoxia. Yellow - high 
abundance, purple - low abundance. [C] Significantly altered carnitine metabolites between 
normoxia and hypoxia. [D] Schematic of mitochondrial carnitine shuttling. [E] Glycolytic 
intermediates identified as significantly altered. Arrow showing the direction of the glycolytic 
pathway. Data generated from 4 separate monocyte preparations. Statistically analysed by 










Figure 3. Carnitine modulation implicates a role for FAO in the production of pro-
inflammatory mediators. [A] Monocytes were pre-treated with ETO (50 µM) for 1h and 
cultured for 16h in normoxia (20% O2) or hypoxia (1% O2) ± LPS (10 ng/ml). Supernatant was 
analysed by ELISA. Data statistically analysed by Wilcoxon rank test. N = 6. [B] Monocytes 
cultured for 16h in normoxia or hypoxia ± LPS ± L-carnitine supplementation (10 mM; 
LCAR). Supernatant was assessed by ELISA. Data statistically analysed by Wilcoxon rank 
test. N = 7 (separate donor cohort to [A]).  Dots are indicative of separate donors. * p ≤ 0.05, 







Figure 4. Monocytes transcriptionally alter CCL20 and fatty acid metabolic pathways 
when they infiltrate the RA synovial environment. [A-C] Microarray gene expression 
profile of circulating monocytes and RA-SF macrophages. [A] Volcano plot of circulating 
monocytes vs RA-SF macrophages. Significant genes (adjusted p < 0.05, 2-fold cut off) are 
shown in red and non−significant genes in black. A positive fold change indicates higher 
expression in macrophages than in monocytes. [B] Gene expression levels of CCL20 illustrated 
as a Z-score (distance from the mean in units of standard deviations). [C] Fatty acid-associated 
pathways identified as being significantly different in RA-SF macrophages after 
hypergeometric pathway analysis. Number of altered genes identified in each pathway 














Figure 5. RA-SF increases the abundance of carnitine metabolites in human monocytes. 
[A-C] Monocytes were exposed to hypoxia for 4h and left either unstimulated or stimulated 
with LPS (10 ng/ml) or RA-SF (10%). The intracellular metabolites were harvested and 
analysed by LC-MS. [A] PCA analysis of the metabolic profiles of monocytes under each 
condition. [B] Heatmap of significantly increased metabolites in RA-SF treated monocytes in 
comparison to both unstimulated (unstim) and LPS stimulated monocytes (p < 0.05; Mann 
Whitney test). Yellow indicates high abundance and purple indicates low abundance. N = 4. 
[C] Carnitines and acylcarnitines that were altered in RA-SF monocytes in comparison to 







Figure 6. Exogenous carnitine increases CCL20 production in RA-SF treated monocytes 
in hypoxia. [A] Human monocytes were either pre-treated for 1h with ETO (50 µM) or [B] 
supplemented with L-carnitine (10 mM; LCAR) and left unstimulated or stimulated with RA-
SF (10% in media). The cells were cultured for 16h in hypoxia (1% O2) and the supernatants 
harvested and analysed by CCL20 ELISA. The levels of CCL20 in the RA-SF media was 
analysed to give baseline levels of each (dotted line). Dots are indicative of separate healthy 
donors of monocytes with line showing the Median. N = 5-7. Statistically analysed by 

















Supplementary Figure 1. Monocytes increase glycolytic gene expression under hypoxia. 
Monocytes were cultured in normoxia or hypoxia for 4 hours and the expression of genes of 
the glycolytic pathway were assessed by qPCR. Line shows the Mean. Statistically analysed 















Supplementary Figure 2. Hypoxia increases the abundance of purine metabolites in 
human monocytes. Schematic showing the purine metabolic pathway for the synthesis of 
DNA and RNA. Metabolites in dashed circles indicate those that showed alterations between 
normoxia and hypoxia after 4 hours. The levels of these metabolites are shown graphically. 
The data was generated from 4 separate monocyte preparations. The data was statistically 

















Supplemental Figure 3. High doses of carnitine negatively impact monocyte viability. 
Monocytes were cultured in normoxia with increasing doses of L-carnitine (LCAR; 0-20 mM) 
for 4 hours and toxicity was assessed by MTT assay. Dots indicative of the Mean ± SD. 







Supplementary Figure 4. Pathways associated with fatty acid metabolism are altered in 
RA-SF macrophages in comparison to blood monocytes. Box-plots illustrating the 
expression levels of significantly altered genes within the fatty acid metabolic pathways 











Supplementary Figure 5. Intermediates of creatinine biosynthesis are increased after 
stimulation with RA-SF in comparison to unstimulated and LPS stimulated monocytes. 
Monocytes were exposed to hypoxia for 4 hours and left either unstimulated or stimulated with 
LPS (10 ng/ml) or RA-SF (10%). The intracellular metabolites were harvested and analysed 
by LC-MS. Schematic of creatinine biosynthesis which branches off the urea cycle. Creatinine 
biosynthesis intermediates which were putatively identified shown graphically. Dots indicative 
















Supplementary Figure 6. Purine metabolism is altered in monocytes cultured in RA-SF 
in comparison to LPS and unstimulated cells. Monocytes were exposed to hypoxia for 4 
hours and left either unstimulated or stimulated with LPS (10 ng/ml) or RA-SF (10%). The 
intracellular metabolites were harvested and analysed by LC-MS. Schematic showing the 
purine metabolic pathway for the synthesis of DNA and RNA. Metabolites in dashed circles 
indicate metabolites which were putatively identified in the dataset. The levels of these 
metabolites are shown graphically. Dots indicative of separate donors and line showing the 


























Supplementary Figure 7. ATP abundance in monocytes after LPS and RA-SF 
stimulation. Monocytes were cultured in hypoxia and stimulated with RA-SF for 4 hours. ATP 
abundance was determined via LC-MS. Dots indicative of separate donors and line showing 







































Supplementary Table 1. Significantly altered metabolites in hypoxic conditions in 














Supplementary Table S2. Putatively identified metabolites in hypoxia with or without LPS 
or RA synovial fluid stimulation. (see attached xls file). 
  
KEGG ID Metabolite Pathway Standard P value Change 
C00093 sn-Glycerol 3-phosphate Glycerolipid Metabolism Yes 0.0286 Up 
C03017 O-Propanoylcarnitine Fatty Acid metabolism  0.0286 Down 
C00118 D-Glyceraldehyde 3-phosphate Glycolysis / PPP  0.0286 Up 
No 
KEGG 
N-(octanoyl)-L-homoserine   0.0286 Down 
C00354 D-Fructose 1_6-bisphosphate Glycolysis  0.0286 Up 
C03901 Thiomorpholine 3-carboxylate   0.0286 Down 
C00197 3-Phospho-D-glycerate Glycolysis / PPP Yes 0.0286 Up 
C00065 L-Serine Glycine, serine, threonine 
metabolism 
Yes 0.0286 Up 
C03771 5-Guanidino-2-oxopentanoate Arginine & proline metabolism  0.0286 Down 
C03741 (S)-4-Amino-5-oxopentanoate   0.0286 Down 
C00042 Succinate Tricarboxylic acid cycle Yes 0.0286 Down 
C02504 2-Isopropylmaleate Valine, leucine and isoleucine 
biosynthesis 
 0.0286 Down 
C00130 IMP Purine Metabolism Yes 0.0286 Up 
C00670 sn-glycero-3-Phosphocholine Glycerophospholipid 
metabolism 
Yes 0.0286 Up 
C03248 Acetylenedicarboxylate Pyruvate Metabolism  0.0286 Down 
C03824 2-Aminomuconate semialdehyde Tryptophan metabolism  0.0286 Down 
C00327 L-Citrulline Arginine biosynthesis Yes 0.0286 Up 
C13050 Cyclic ADP-ribose Calcium signalling pathway  0.0286 Down 
C00668 D-Glucose Glycolysis / PPP Yes 0.0286 Up 
C00064 L-Glutamine Amino acid & Nucleotide 
metabolism 
Yes 0.0286 Up 
C06455 Hydroxymethylphosphonate Phosphonate metabolism  0.0286 Up 
C00262 Hypoxanthine Purine Metabolism Yes 0.0294 Up 
C00447 D-Sedoheptulose 1_7-
bisphosphate 
Energy metabolism  0.0294 Up 
 
Supplementary Online Methods 
 
Primary human monocyte isolation and culture 
Peripheral blood mononuclear cells (PBMCs) were separated from human blood buffy coats 
by density gradient centrifugation using Ficoll® Paque Plus (Sigma-Aldrich) and standard 
procedures. To purify the monocyte population, the EasySep monocyte enrichment kit, 
without CD16 depletion (StemCell Technologies), was used according to manufacturer’s 
instructions. Enriched monocytes were re-suspended at a density of 1x106/ml in monocyte 
medium (RPMI 1640 containing 10% human pooled plasma (BioWest), 2 mM L-glutamine, 
1% pen-strep). For stimulation, human monocytes were stimulated with 10 ng/ml LPS-EK 
ultrapure (Invivogen). Synovial fluid aspirates were collected from patients with active 
disease and centrifuged at 900g for 10 minutes at 4°C to remove cells and stored at -80°C. 
Monocytes were cultured in media containing 10% RA-SF. For carnitine manipulation, 
monocytes were treated with 10 mM L-carnitine (Sigma-Aldrich) simultaneously with LPS 
or RA synovial fluid stimulation. Monocytes were pre-treated for 1 hour with etomoxir 
(ETO; Sigma-Aldrich) at 50 µM. 
Induction of hypoxia 
For the induction of hypoxia (1% O2), an airtight hypoxic chamber was utilised (Billups-
Rothenburg). The chamber was purged with a speciality gas mixture from British Oxygen 
Company (BOC), containing 1% O2, 5% CO2 and N2 balance, through an inlet port at a flow 
rate of 40 L per minute, for 3 minutes. The inlet and outlet port were sealed closed and the 
chamber was placed in a standard 37°C tissue culture incubator. For culture in normoxia, 
cells were cultured in ambient oxygen in a standard 37°C tissue culture incubator. 
Immunoblotting 
1x106 monocytes were lysed directly in Laemmli buffer (BioRad), boiled and loaded into 
NuPAGE pre-cast 4-12% Bis-Tris Gel (Thermo Fisher). Gels were transferred to PVDF 
 
membranes and subsequently blocked with PBS-T containing 5% non-fat dried milk and 
incubated with antibodies specific for mouse anti-human HIF-1α (BD Transduction 
Laboratories) and GAPDH XP® (CST). Membranes were washed and incubated with HRP-
labelled secondary antibody (Dako). After subsequent washing, membranes were incubated 
in WestPico substrate solution (Thermo Fisher) and visualised using an Azure Biosystems 
c500 Western Blot imaging system. 
Extraction of monocyte intracellular metabolites 
In order to quench cellular metabolism rapidly and maintain this, all reagents, vessels and 
procedures were performed at ≤4°C. Tissue culture plates containing monocytes were 
immediately placed on ice, and monocytes were aspirated and transferred to 15 ml centrifuge 
tubes containing ice-cold DPBS. Each well was flushed with ice-cold DPBS to remove all 
cells, and the flush was combined with the initial aspirated sample. Samples were centrifuged 
at 300g for 5 minutes at 4°C. Pellets were re-suspended in 1ml ice-cold PBS and centrifuged 
at 4°C. Pellets were re-suspended in 200 µl ice-cold extraction solvent (chloroform:methanol: 
water at a 1:3:1 ratio). The tubes were incubated for 1 hour at 4°C in an Eppendorf 
ThermoMixer® with shaking at 1500 rpm. Samples were centrifuged at 17,000g for 10 
minutes at 4°C. Supernatant containing metabolites were collected into screw-capped vials 
and stored at -80°C until analysis. A pooled sample containing an equal volume of all 
samples (to a total of 200 µl) was generated. This sample was run during mass spectrometry 
analysis to assess the reproducibility of the mass spectrometer. 
Untargeted Liquid Chromatography Mass Spectrometry (LC-MS) 
Hydrophilic interaction liquid chromatography (HILIC) was carried out on a Dionex 
UltiMate 3000 RSLC system (Thermo Fisher) using a ZIC-pHILIC column (150 mm × 4.6 
mm, 5 μm column, Merck Sequant). For the MS analysis, a Thermo Orbitrap Q Exactive 
(Thermo Fisher) was operated in both positive and negative mode. The column was 
 
maintained at 30°C. The samples were eluted with a linear gradient from 80% acetonitrile to 
20% ammonium carbonate (20 mM in water) over 24 minutes, at a flow rate of 0.3 ml/min. 
Each sample was run in a random order, with a pooled sample run between every 5 samples 
to assess for reproducibility. The MS settings were as follows: 70,000 resolution; m/z range 
of 70-1050; automatic gain control target of 1e6; sheath gas flow rate of 40; auxillary gas 
flow rate 5; sweep gas flow rate 1; probe temperature of 150°C and capillary temperature of 
320°C. For positive mode ionisation: source voltage +3.8 kV, S-Lens RF Level 30.00, S-Lens 
Voltage -25.00 (V), Skimmer Voltage -15.00 (V), Inject Flatopole Offset -8.00 (V), Bent 
Flatapole DC -6.00 (V). For negative mode ionisation: source voltage-3.8 kV. The calibration 
mass range was extended to cover small metabolites by inclusion of low-mass calibrants with 
the standard Thermo calmix masses (below m/z 138), butylamine (C4H11N1) for positive ion 
electrospray ionisation (PIESI) mode (m/z 74.096426) and COF3 for negative ion electospray 
ionisation (NIESI) mode (m/z 84.9906726). 
Processing of MS data 
Processing of the raw data and analysis was performed using a processing pipeline through 
IDEOM Excel based software (17). According to the metabolomics standards initiative 
(MSI), metabolite identifications (MSI level 1) are given when more than one feature 
matches an authentic standard (i.e. mass and retention time) and annotations are made when 
matching to a metabolite is made by mass only (MSI level 2), and should be considered 
putative. Included in the MS analysis was a mixture of 240 standards. These covered a range 
of metabolic pathways to allow metabolite identifications to be made. In the comparisons tab 
of the IDEOM Excel spreadsheet, the peaks were visually interrogated. Peaks not showing a 
Gaussian-type shape were rejected as a false identification. Due to higher than expected 
variation in the per sample total intensities of the LPS/SF experiment, the metabolomic data 
was normalised by sample total intensity. To allow for reasonable numbers the per sample 
 
total intensity across all metabolites was set to 1,000,000. The normalised data was used in 
generating the principal component analysis (PCA) and heatmaps. PCA was performed on 
the processed metabolite data using the R (v.3.4.4) function prcomp. Ellipses were drawn 
around sample groups using the R function ellipse, centring on the mean x and y coordinates 
and scaled to 1.5 times the standard deviation. Heatmaps of significant metabolites were 
hierarchically clustered using the R package hclust, with the distance method Spearman and 
cluster method Average. The data was then scaled into per metabolite z-scores (i.e. distance 
from the mean in units of standard deviations) using the R function scale. 
Microarray Analysis 
RNA purification and microarray analysis of samples from matched RA blood and SF 
derived CD14+ cells was conducted as previously described (18). In brief, Raw .CEL files 
were processed and normalised using the R (v3.4.4). Array quality was assessed before and 
after normalisation. The R WGCNA package was used to collapse multiple genes down to a 
single value using the “MaxMean” method. This reduced the number of features from 54,675 
to 21,336 unique features. Differential expression was determined using the R package 
LIMMA (19) with a significance threshold of adjusted p < 0.05 and a fold change > 2. 
Enriched gene-sets were determined using a hypergeometric test with Benjamini-Hochberg 
correction at p < 0.05. The collapsed probe-set was used as the background, and a 
combination of the following MsigDB (20) collections were used in the analysis: canonical 
pathways, BIOCARTA, KEGG, REACTOME and GO. 
ELISA & Meso-Scale Discovery (MSD) 
Supernatant analysis of IL-1β (Life Technologies) and CCL20 (R&D Systems) was carried 
out by ELISA according to the manufacturer’s instructions. The plates were read using a 
Tecan Sunrise microplate reader at 450 nm (650 nm reference). The data was exported to 
 
Excel and a standard curve was generated. The concentrations of the samples were calculated 
using the equation of the straight line. 
TNFα, IL-1β and IL-6 supernatant were also analysed by using the V-PLEX Pro-
inflammatory panel 1 from MSD according to the manufacturer’s protocol. The plates were 
read on a MESO Quickplex SQ 120 (MSD) and the electro-chemiluminescent signal 
determined by using Discovery Workbench 4.0 (MSD) software. 
Statistical Analysis 
Statistical analysis was performed in GraphPad Prism 6 software. All data are shown as the 
mean ± standard deviation (SD) unless otherwise stated. The statistical test used for each 
experiment is indicated in the figure legend. A p value of less than 0.05 was considered 
significant.  
Data Availability 
The microarray array data is MIAME compliant and has been deposited to the ArrayExpress 
database (http://www.ebi.ac.uk/arrayexpress) with the accession number: E-MEXP-3890. 
Metabolomic data will be deposited to the MetaboLights database 
(https://www.ebi.ac.uk/metabolights). 
